SCHEMBL4936889

SCHEMBL4936889

O=C1C[C@@H](C(=O)O)Oc2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.60
ADORA3 P0DMS8 3/20 0.60
AR P10275 3/20 0.60
KDM4E B2RXH2 1/20 0.60
CYP19A1 P11511 1/20 0.60
HSD17B10 Q99714 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.58
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
MAPT P10636 2/20 0.53
HSD11B1 P28845 1/20 0.53
AKR1C3 P42330 1/20 0.53
CYP3A4 P08684 1/20 0.53
MAPK1 P28482 1/20 0.53
AXL P30530 1/20 0.49
SIGMAR1 Q99720 1/20 0.45
ABCB1 P08183 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22617257 1.00 MAOB (0.60) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL1533015 1.00 MAOB (0.60) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL29540767 1.00 MAOB (0.60) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL4931666 1.00 MAOB (0.60) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL29540680 1.00 MAOB (0.60) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL29364688 1.00 MAOB (0.60) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL22617253 1.00 MAOB (0.60) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL22617487 1.00 MAOB (0.60) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL29499451 0.86 MAOB (0.56) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL12561159 0.86 MAOB (0.56) MAOBADORA3ARKDM4ECYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114401952-A Substituted cycloalkyl compounds as modulators of integrated stress pathways 卡里科生命科学有限责任公司 2022-04-26 CN disclosed
EP-3962899-A1 SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2022-03-09 EP disclosed
US-20080039639-A1 Chromane and chromene derivatives and uses thereof WYETH (US) 2008-02-14 US disclosed
US-20080039639-A1 Chromane and chromene derivatives and uses thereof WYETH (US) 2008-02-14 US disclosed
US-20080039639-A1 Chromane and chromene derivatives and uses thereof WYETH (US) 2008-02-14 US disclosed
WO-2007123941-A2 CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF WYETH (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039639-A1 Chromane and chromene derivatives and uses thereof HTR1A, CHRM1, HTR2C MAOB 200/4885ADORA3 82/4885AR 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.